| Treatment options for refractory Wegener's granulomatosis: a role for rituximab? | |
| | |
MedLine Citation:
|
PMID: 17979026 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Wegener's granulomatosis (WG) is a small-vessel vasculitis of unknown etiology, involving mainly the upper airways, lungs and kidneys. Organ inflammatory damage is mediated by anti-neutrophil cytoplasm antibodies, and their detection is a component of the diagnostic work-up as well as clinical signs and symptoms, and histopathological biopsy abnormalities. Conventional therapeutic regimens, such as cyclophosphamide and corticosteroids, can be used to induce and maintain disease remission. Alternatively, other cytotoxic agents (eg, methotrexate or mycophenolate mofetil), anti-TNFalpha agents (eg, infliximab or etanercept) or anti-lymphocyte antibodies (eg, rituximab) can be used. Rituximab, a mAb which targets CD20+ B-cells, is currently used in the treatment non-Hodgkin's lymphoma and rheumatoid arthritis, and is being investigated for refractory WG therapy and other autoimmune diseases. |
| | |
Authors:
|
Sabina A Antoniu |
Related Documents
:
|
18441766 - Adult henoch-schönlein purpura in a patient with myelodysplastic syndrome and a histor... 18037116 - Takayasu arteritis: what is the long-term prognosis? 6826806 - Minidose heparin therapy for vasculitis of atrophie blanche. 8255836 - Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodi... 22905296 - Emerging and under-recognized chagas cardiomyopathy in non-endemic countries. 12934726 - Attenuation of exposure-response curves in occupational cohort studies at high exposure... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 8 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-11-05 Completed Date: 2008-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 927-32 Citation Subset: IM |
Affiliation:
|
Gr T Popa University of Medicine and Pharmacy, Division of Pulmonary Disease, 30 Dr I Cihac Str, Iasi 700115, Romania. saantoniu@pneumo.umfiasi.ro |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Drug Therapy / methods*, trends Hematopoietic Stem Cell Transplantation / methods Humans Plasmapheresis / methods Treatment Outcome Wegener Granulomatosis / immunology, pathology, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Update on infantile colic and management options.
Next Document: Activated protein C: controversy and hope in the treatment of sepsis.